A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination

Clinical Trial ID NCT00335270

PubWeight™ 0.00^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00335270

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.	JAMA	2000	6.49
2	Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.	AIDS	1999	2.47
3	Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.	Arch Intern Med	2000	2.11
4	Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.	AIDS	1998	2.05
5	The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1.	AIDS	1999	1.78
6	The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.	J Acquir Immune Defic Syndr	2004	1.60
7	Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.	Clin Infect Dis	2003	1.42
8	Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.	Clin Infect Dis	2000	1.18
9	Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor.	Clin Ther	2000	0.91
10	Amprenavir: a review of its clinical potential in patients with HIV infection.	Drugs	2000	0.90